ClinicalTrials.gg
CompletedNCT06716879Updated Feb 18, 2026

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants

A Phase 1 interventional study of Donzakimig and Placebo in Healthy Participants, sponsored by UCB Biopharma SRL. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of the study is to investigate the safety, tolerability, and pharmacokinetic parameters of 2 dose strengths of donzakimig, each administered subcutaneously as a single dose, in healthy Chinese and Japanese study participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • donzakimig
  • UCB1381
  • Phase 1
  • Healthy Participants
03

In context

Lead sponsor

UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 17 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must be 18 to 55 years of age inclusive at the time of signing the form (ICF)
  • Study participant who is overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac assessment
  • Chinese study participant who is of Chinese descent as evidenced in appearance and verbal confirmation of familial heritage and is of Chinese descent with all 4 grandparents, OR Japanese study participant who is of Japanese descent as evidenced in appearance and verbal confirmation of familial heritage and is of Japanese descent with all 4 grandparents
  • Study participant has a within the range of 18 to 30kg/m2 (inclusive)
  • Study participant can be male or female

Exclusion criteria

Exclusion criteria

  • Study participant has multiple or severe drug allergies (including to humanized monoclonal antibodyies (mAbs), intolerance to topical , severe post-treatment reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis), known relevant allergy (not including mild seasonal hay fever and/or conjunctivitis or low grade food intolerances), pre-existing history of a relevant allergic condition, or a predisposition for an allergic reaction, as judged by the Investigator
  • Study participant has a recent history (within 6 months prior to Screening) or currently active clinically-significant bacterial, fungal, endoparasite (including the presence of ova, cysts, or parasites detected in stool sample provided at Screening), or viral (including hospitalization for coronavirus disease 2019 [COVID-19]) infection, as judged by the Investigator
  • Study participant has a history of inflammatory bowel disease (eg, Crohn's disease or ulcerative colitis)
  • Study participant has a history of diabetes
  • Study participant has received any vaccination within 8 weeks for (including attenuated) and 4 weeks for nonlive vaccines prior to the Baseline Visit or is anticipated to do so within 60 days after the dose of IMP
  • Study participant has received Bacillus Calmette-Guerin vaccinations within 1 year prior to the Baseline Visit or will receive them within 90 days after the dose of IMP
  • Study participant has participated in another study of an IMP or has received any biologic agent within the 30 days prior to Screening (or 5 half-lives, whichever is longer)
  • Study participant has had a positive (HIV) antibody test
  • Study participant has the presence of either core antibody or hepatitis B surface antigen at Screening or within 3 months prior to dosing
  • Study participant has a positive antibody test result at Screening or within 3 months prior to Screening.
  • Study participant has a positive hepatitis C ribonucleic acid (RNA) test result at Screening or within 3 months prior to Screening
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Low Dose of donzakimig in Chinese participants

    Chinese participants will be randomized to receive a predefined dosage of donzakimig.

    Drug: Donzakimig

  • Experimental
    High Dose of donzakimig in Chinese participants

    Chinese participants will be randomized to receive a predefined dosage of donzakimig.

    Drug: Donzakimig

  • Placebo comparator
    Low Dose of placebo in Chinese participants

    Chinese participants will be randomized to receive a predefined dosage of placebo.

    Drug: Placebo

  • Placebo comparator
    High Dose of placebo in Chinese participants

    Chinese participants will be randomized to receive a predefined dosage of placebo.

    Drug: Placebo

  • Experimental
    Low Dose of donzakimig in Japanese participants

    Japanese participants will be randomized to receive a predefined dosage of donzakimig.

    Drug: Donzakimig

  • Experimental
    High Dose of donzakimig in Japanese participants

    Japanese participants will be randomized to receive a predefined dosage of donzakimig.

    Drug: Donzakimig

  • Placebo comparator
    Low Dose of placebo in Japanese participants

    Japanese participants will be randomized to receive a predefined dosage of placebo.

    Drug: Placebo

  • Placebo comparator
    High Dose of placebo in Japanese participants

    Japanese participants will be randomized to receive a predefined dosage of placebo.

    Drug: Placebo

Interventions

  • DrugDonzakimig

    Drug: Donzakimig Pharmaceutical form: Subcutaneous solution

    Also known as: UCB1381

  • DrugPlacebo

    Drug: Placebo Pharmaceutical form: Subcutaneous solution

06

What researchers measure

Primary outcomes

  1. Occurrence of treatment-emergent adverse events (TEAEs)

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Treatment emergent adverse events (TEAEs) are adverse events not present prior to the pharmaceutical product administration or an already present event that worsens either in intensity or frequency

    Time frame: From Baseline to End of Study visit (up to Day 57)

  2. Occurrence of serious treatment-emergent adverse events (serious TEAEs)

    A serious treatment-emergent adverse event (serious TEAE) is defined as any untoward medical occurrence that, at any dose: Results in death Is life-threatening Requires inpatient hospitalization or prolongation of existing hospitalization Results in persistent disability/incapacity Is a congenital anomaly/birth defect Important medical events

    Time frame: From Baseline to End of Study visit (up to Day 57)

  3. Maximum plasma concentration (Cmax) of donzakimig

    Cmax: Maximum plasma concentration of donzakimig

    Time frame: Sampling timepoints will be on Day 1 (D1): at predose and 6 hours (h), 24h (D2), 72h (D4), 120h (D6), D8, D15, D22, D36, and D57 after investigational medicinal product (IMP) administration.

  4. Area under the plasma concentration-time curve from time 0 to t of donzakimig

    AUC0-t: Area under the plasma concentration-time curve from from 0 to the time (t) of the last quantifiable concentration.

    Time frame: Sampling timepoints will be on Day 1 (D1): at predose and 6 hours (h), 24h (D2), 72h (D4), 120h (D6), D8, D15, D22, D36, and D57 after investigational medicinal product (IMP) administration.

  5. Area under the plasma concentration-time curve from zero to infinity of donzakimig

    AUC: Area under the plasma concentration-time curve from zero to infinity of donzakimig

    Time frame: Sampling timepoints will be on Day 1 (D1): at predose and 6 hours (h), 24h (D2), 72h (D4), 120h (D6), D8, D15, D22, D36, and D57 after investigational medicinal product (IMP) administration.

07

Study locations

1 site
  • UP0142 1
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: No — Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Apr 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2024
First posted
Dec 4, 2024
StartActual
Dec 6, 2024
Primary completionActual
Apr 4, 2025
CompletionActual
Apr 4, 2025
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06716879
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Dec 4, 2024
Start date
Dec 6, 2024
Primary completion
Apr 4, 2025
Completion
Apr 4, 2025
Last update
Feb 18, 2026

Study contacts

UCB Cares
study director · 0018445992273

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion